Sanara MedTech (Nasdaq: SMTI) is facing fresh legal scrutiny following its agreement to be acquired by MiMedx in a transaction valued at approximately $350 million, as shareholder rights law firm Ademi LLP announced an investigation into whether the company’s board fulfilled its fiduciary duties during the sale process.
The investigation centers on whether Sanara’s directors negotiated the best possible outcome for shareholders or agreed to deal terms that could discourage competing acquisition offers.
Investigation Focuses on Board Decisions
According to Ademi LLP, the firm is examining potential breaches of fiduciary duty and other legal violations related to the acquisition agreement. The investigation will assess whether Sanara’s board acted in the best interests of shareholders while negotiating the merger.
Law firms frequently launch these investigations after public company acquisitions, particularly when transactions include provisions that may limit competing bids or provide significant benefits to company executives. While such announcements do not necessarily indicate wrongdoing, they often serve as an early step in determining whether shareholder litigation is warranted.
Inside the MiMedx-Sanara Transaction
Under the terms of the agreement, Sanara shareholders will receive:
- $33.00 in cash
- 0.4735 shares of MiMedx common stock for each Sanara share
Based on MiMedx’s five-day average closing price of $4.22 through July 28, 2026, the stock component is valued at approximately $2.00 per Sanara share, bringing the total consideration to $35.00 per share.
The combined cash-and-stock transaction values the deal at an enterprise value of roughly $350 million.
The stock component means the ultimate value shareholders receive could fluctuate depending on MiMedx’s share price before the transaction closes—a common feature in hybrid merger agreements that can expose investors to market volatility.
Deal Protections Under the Microscope
A key area of Ademi LLP’s investigation involves provisions that allegedly make it more difficult for Sanara to entertain competing acquisition offers.
According to the firm, the merger agreement includes a termination fee or similar penalty that would apply if Sanara accepts a superior proposal from another bidder. Such “deal protection” mechanisms are standard in many mergers and acquisitions, but they can become contentious if investors believe they effectively discourage higher competing offers.
The investigation will also review change-of-control arrangements that could provide substantial financial benefits to Sanara insiders upon completion of the acquisition. Executive compensation tied to mergers is common across public company transactions, but it often attracts scrutiny when shareholders question whether management’s incentives were fully aligned with maximizing shareholder value.
A Common Pattern in Public Company M&A
Shareholder investigations have become a routine feature of public-company mergers, particularly in the healthcare and medical technology sectors, where consolidation continues to accelerate. Legal firms frequently examine board processes, fairness opinions, executive compensation, and merger protections after acquisition announcements.
In many cases, investigations conclude without litigation or result only in additional disclosures to shareholders. Others may develop into lawsuits seeking revised deal terms, enhanced disclosures, or, less commonly, efforts to block a transaction.
For investors, an announced investigation does not automatically signal misconduct. Instead, it reflects increased legal scrutiny over whether directors met their obligations during negotiations.
Sanara shareholders interested in the investigation can contact Ademi LLP for additional information regarding their legal rights and the firm’s ongoing review.
Get in touch with our fintech expert
